Recent news on Interferon Alfa-2A

International panel issues new HIV/HCV co-infection guidelines  -  May 24, 2007
Aidsmap,Therefore, the panel recommended the same standard doses used for HCV mono-infected patients: 180 mcg/week of pegylated interferon alfa-2a (Pegasys) or 1.5

Cure for hepatitis C announced  -  May 22, 2007
HULIQ,Disease Week conference in Washington, DC VCU was among about 40 sites worldwide studying pegylated interferon alfa-2a, manufactured by Roche Inc.

Researchers find cure for hepatitis C  -  May 21, 2007
South Asian Women's Forum,VCU was among about 40 sites worldwide studying pegylated interferon alfa-2a, manufactured by Roche Inc. Ninety nine percent of patients with hepatitis C

Dose modification associated with poorer response to HCV therapy ...  -  Apr 29, 2007
Aidsmap,Patients treated with pegylated interferon-alfa-2a were significantly more likely to reduce the dose of either pegylated interferon (p = 0.03), or ribavirin

New deals for ProBioGens cell engineering group  -  Apr 25, 2007
In-PharmaTechnologist.com,It also sells biosimilar versions of interferon alfa-2a and pegylated interferon alfa-2a., sold by Roche as Roferon-A and Pegasys, respectively.

Telaprevir Plus Peginterferon Alfa-2a and Ribavirin Drives 79% of ...  -  Apr 16, 2007
DG News2007 -- The triple combination therapy of the investigational drug telaprevir plus standard treatment with pegylated interferon alfa-2a and ribavirin

EASL: Telaprevir Shows Promise of Shortened Hepatitis C Therapy  -  Apr 16, 2007
MedPage Today,Standard of care for hepatitis C virus is 48 weeks of pegylated interferon alfa-2a -- injected one a week, plus oral ribavirin twice a day for 48 weeks.

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
Juraforum.de,Each weekly subcutaneous injectioncontains 180 mcg of pegylated interferon alfa-2a (40KD), which is theapproved dose for all patients, regardless of body

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PR Newswire (press release),...novel combination of valopicitabine (NM283) and pegylated interferon alfa-2a (Pegasys(R)) in both treatment-naive and treatment- experienced patients

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PharmaLive.com (press release),Inc. today announced results from two phase IIb studies of the novel combination of valopicitabine (NM283) and pegylated interferon alfa-2a (Pegasys(R))

Analysis: Shorter therapy for hepatitis C?  -  Apr 16, 2007
Science Daily (press release)...interferon alfa-2a and ribavirin compared to 11 percent of patients treated with just pegylated interferon alfa-2a and ribavirin," he told UPI.

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Apr 6, 2007
Drug Newswire (press release),Each weekly subcutaneous injection contains 180 microg of pegylated interferon alfa-2a (40KD), which is the approved dose for all patients, regardless of

Vertex Pharmaceuticals - Interim Results Presented at EASL from ...  -  Apr 16, 2007
Oxfordshire Bioscience Network (press release),A total of 250 patients were enrolled in PROVE 1 and received at least one dose of telaprevir or placebo in addition to Peg-interferon alfa-2a (peg-IFN) +

Idenix Pharma Reveal Results From 2 Phase IIb Studies Of ...  -  Apr 12, 2007
Trading Markets,...pegylated interferon alfa-2a in both treatment-naive and treatment, experienced patients infected with the genotype-1 strain of the hepatitis C virus.

Idenix Midstage Study Results Mixed  -  Apr 12, 2007
Forbes,...trial involved 173 patients who had not previously been treated with the combination of valopicitabine and Pegasys, or pegylated interferon alfa-2a.

Analysis: Total hepatitis C cure possible  -  Apr 12, 2007
Science Daily (press release)All these patients had a sustained virologic response when treated with pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with

Nautilus Biotech begins Phase I clinical trial in the USA for ...  -  Apr 2, 2007
PipelineReview.com (press release),...which will be compared to SC administered IntronA(R) (a Schering-Plough product) and Pegasys(R) (pegylated Interferon alfa-2a (40KD), a Roche product).

Idenix Announces Data Presentations at the 2007 Digestive Disease ...  -  Apr 19, 2007
PharmaLive.com (press release),Atlanta Gastroenterology Associations and Emory University, Atlanta, GA, will present "Valopicitabine (NM283) Plus Peg-Interferon Alfa-2a (peg-IFN) in

Idenix Announces Data Presentations at the 2007 Digestive Disease ...  -  Apr 18, 2007
PR-Inside.com (Pressemitteilung),...will present "Valopicitabine (NM283) Plus Peg-Interferon Alfa-2a (peg-IFN) in Treatment-Naive Patients With HCV-1 Infection: Preliminary Results At Weeks 24

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Mar 5, 2007
PR Newswire UK (press release),Each weekly subcutaneous injection contains 180 microg of pegylated interferon alfa-2a (40KD), which is the approved dose for all patients, regardless of

Vertex Pharmaceuticals Reports 2006 Financial Results  -  Feb 1, 2007
Earthtimes.org...with telaprevir dosed at 750 mg every eight hours (q8h) in combination with standard doses of pegylated interferon alfa-2a (peg-IFN) and ribavirin (RBV)

Case 2-2007 — A 49-Year-Old Woman with a Pigmented Lesion on the Arm  -  Jan 17, 2007
New England Journal of Medicine (subscription),Initial studies of interferon alfa-2a (at a dose of 3 million IU given subcutaneously three times per week for 3 years) in patients with positive lymph

Interim Analysis Of Phase III Trial Shows Avastin Plus Interferon ...  -  Dec 25, 2006
Medical News Today (press release),Patients were randomized to receive either standard therapy of interferon alfa-2a plus placebo or interferon alfa-2a plus Avastin.

Vertex Pharmaceuticals Announces Results Of First Interim Safety ...  -  Dec 24, 2006
Medical News Today (press release),A total of 250 patients were enrolled and in addition to Peg-interferon alfa-2a (peg-IFN) + ribavirin (RBV) received at least one dose of telaprevir or

Pakistani doctor to be honoured for a research on Hepatitis C ...  -  Jan 2, 2007
Associated Press of Pakistan,...standard Interferon and Ribavirin and Efficiency of Peg -Interferon Alfa 2a/Ribavirin for HEPC Genotype 3 Relapsers with standard interferon/Ribavirin.

Expectations Upbeat Despite The Slowdown Suggested By Analysts ...  -  Jan 9, 2007
Trading Markets,According to the company, AVOREN, a randomized Phase III clinical study of Avastin in combination with interferon alfa-2a therapy in patients with

SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple ...  -  Dec 28, 2006
PharmaLive.com (press release),Patients have been randomized to receive either ZADAXIN or a placebo, and all patients are receiving pegylated interferon alfa-2a and ribavirin.

Antiretroviral Therapy for HIV: New Data From HIV 8 in Glasgow  -  Dec 26, 2006
Medscape (subscription)The PRESCO trial: role of extended duration of therapy with pegylated interferon alfa-2a plus weight-based ribavirin dose in 389 HCV/HIV co-infected

Antiretroviral Therapy for HIV: New Data From HIV 8 in Glasgow  -  26 Dec 2006
Medscape (subscription)The PRESCO trial: role of extended duration of therapy with pegylated interferon alfa-2a plus weight-based ribavirin dose in 389 HCV/HIV co-infected

Interim Analysis Of Phase III Trial Shows Avastin Plus Interferon ...  -  Dec 25, 2006
Medical News Today (press release),Patients were randomized to receive either standard therapy of interferon alfa-2a plus placebo or interferon alfa-2a plus Avastin.

Vertex Pharmaceuticals Announces Results Of First Interim Safety ...  -  Dec 24, 2006
Medical News Today (press release),A total of 250 patients were enrolled and in addition to Peg-interferon alfa-2a (peg-IFN) + ribavirin (RBV) received at least one dose of telaprevir or

Interim Analysis of Phase III Trial Shows Avastin Plus Interferon ...  -  Dec 12, 2006
Drug Newswire (press release),Patients were randomized to receive either standard therapy of interferon alfa-2a plus placebo or interferon alfa-2a plus Avastin.

Genentech's Phase III Trial Of Avastin With Interferon Meets ...  -  Dec 12, 2006
Trading Markets,According to the company, AVOREN, a randomized Phase III clinical study of Avastin (bevacizumab) in combination with interferon alfa-2a therapy in patients

Genentech (DNA) Said Avastin Plus Interferon Therapy Improved ...  -  Dec 12, 2006
StreetInsider.com (subscription),Genentech, Inc. (NYSE: DNA) said interim analysis shows that a randomized Phase III clinical study of Avastin in combination with interferon alfa-2a therapy

Genentech/Roche: another indication for the blockbuster Avastin?  -  Dec 13, 2006
Pharmaceutical Business ReviewThe trial met its primary endpoint by significantly improving progression-free survival in comparison to single-agent interferon alfa-2a.

Avastin shows promise in kidney cancer  -  Dec 13, 2006
Pharma Times (subscription),649 patients with metastatic renal cell carcinoma were randomised to receive standard therapy consisting of interferon alfa-2a plus either placebo or

Market Report -- In Play (DNA)  -  Dec 12, 2006
MSN Money...interim analysis shows that a randomized Phase III clinical study of Avastin in combination with interferon alfa-2a therapy in patients with first-line

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)28 days of the hepatitis C protease inhibitor VX-950, in combination with peg-interferon-alfa-2a and ribavirin, is well-tolerated and demonstrates robust

Results of First Interim Safety and Antiviral Analysis of the ...  -  Dec 13, 2006
PR Newswire UK (press release),In clinical trials, telaprevir is being dosed as 750 mg every eight hours in combination with pegylated interferon alfa-2a (Pegasys(r)), both with and (in

Results of First Interim Safety and Antiviral Analysis of the ...  -  Dec 13, 2006
Earthtimes.orgInclinical trials, telaprevir is being dosed as 750 mg every eight hours incombination with pegylated interferon alfa-2a (Pegasys(r)), both with and (inthe

Vertex Pharmaceuticals Announced Results Of Safety Analysis On ...  -  Dec 13, 2006
Trading Markets,The company said it enrolled 250 patients for the PROVE 1 study, who received Peg-interferon alfa-2a + ribavirin and a dose of telaprevir or placebo.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional